REG - PureTech Health PLC - Transaction in Own Shares
22/12/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231222:nRSV6900Xa&default-theme=true
RNS Number : 6900X PureTech Health PLC 22 December 2023
22 December 2023
PureTech Health plc
Transaction in Own Shares
PureTech Health PLC (the "Company") announces that it has purchased the
following number of its ordinary shares of one pence each through Jefferies
International Limited ("Jefferies"), as part of its Share Buyback Programme,
details of which were announced on 9 May 2022.
Date of purchase: 21 December 2023
Number of ordinary shares purchased: 61,072
Highest price paid per share: 154.20p
Lowest price paid per share: 147.00p
Volume weighted average price paid per share: 150.69p
PureTech intends to retain the purchased shares in treasury.
Following the above transaction, the Company will have 17,578,713 ordinary
shares in treasury and has 271,889,446 ordinary shares in issue (excluding
treasury shares). The total number of voting rights in the Company is
therefore 271,889,446 which may be used by shareholders in their calculations
to determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as
incorporated into UK domestic law by the European Union (Withdrawal) Act 2018)
(the Market Abuse Regulation), detailed information about the individual
purchases is available below.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 27 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both U.S.
FDA clearance and European marketing authorization and a third (KarXT) that
has been filed for FDA approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/) or connect with us on X, formerly known as
Twitter, @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
Individual Transactions
Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number
21/12/2023 08:18:42 578 154 BATE 00383349019TRLO0.1.1
21/12/2023 08:18:42 358 154.2 AQXE 00383349018TRLO0.1.1
21/12/2023 08:18:42 578 154.2 CHIX 00383349020TRLO0.1.1
21/12/2023 08:18:42 189 154 TRQX 00383349021TRLO0.1.1
21/12/2023 08:18:42 578 154.2 XLON 00383349022TRLO0.1.1
21/12/2023 08:27:56 578 153.8 CHIX 00383350179TRLO0.1.1
21/12/2023 08:27:56 578 153.8 XLON 00383350180TRLO0.1.1
21/12/2023 08:28:53 701 153.4 XLON 00383350279TRLO0.1.1
21/12/2023 09:11:06 124 153.4 XLON 00383355130TRLO0.1.1
21/12/2023 09:24:21 578 153.8 CHIX 00383357236TRLO0.1.1
21/12/2023 09:24:21 30 153.6 XLON 00383357237TRLO0.1.1
21/12/2023 09:24:21 366 153.6 CHIX 00383357238TRLO0.1.1
21/12/2023 09:24:21 140 153.6 CHIX 00383357239TRLO0.1.1
21/12/2023 09:24:21 72 153.6 CHIX 00383357240TRLO0.1.1
21/12/2023 09:24:21 1704 153.6 XLON 00383357241TRLO0.1.1
21/12/2023 09:27:51 506 153.4 BATE 00383357657TRLO0.1.1
21/12/2023 09:27:51 358 153.4 AQXE 00383357656TRLO0.1.1
21/12/2023 09:27:51 72 153.4 BATE 00383357658TRLO0.1.1
21/12/2023 09:27:51 189 153.4 TRQX 00383357659TRLO0.1.1
21/12/2023 09:40:15 1734 153 XLON 00383359942TRLO0.1.1
21/12/2023 09:48:44 578 152 CHIX 00383360843TRLO0.1.1
21/12/2023 09:48:44 2312 152 XLON 00383360844TRLO0.1.1
21/12/2023 10:00:49 51 151 XLON 00383362047TRLO0.1.1
21/12/2023 10:00:49 2261 151 XLON 00383362048TRLO0.1.1
21/12/2023 10:03:39 578 150 XLON 00383362645TRLO0.1.1
21/12/2023 10:03:39 909 150 XLON 00383362646TRLO0.1.1
21/12/2023 10:19:54 34 149.2 XLON 00383365810TRLO0.1.1
21/12/2023 10:20:59 16 149.2 XLON 00383365933TRLO0.1.1
21/12/2023 10:21:03 3 149.2 XLON 00383365938TRLO0.1.1
21/12/2023 10:34:13 9 149.2 XLON 00383367570TRLO0.1.1
21/12/2023 10:55:09 578 149.6 CHIX 00383370623TRLO0.1.1
21/12/2023 10:55:09 358 149.2 AQXE 00383370624TRLO0.1.1
21/12/2023 10:55:09 51 149.2 XLON 00383370625TRLO0.1.1
21/12/2023 10:55:09 684 149.2 CHIX 00383370627TRLO0.1.1
21/12/2023 10:55:09 578 149.2 CHIX 00383370626TRLO0.1.1
21/12/2023 10:55:09 1043 149.2 XLON 00383370628TRLO0.1.1
21/12/2023 10:55:09 578 149.2 XLON 00383370629TRLO0.1.1
21/12/2023 10:58:19 578 149 BATE 00383371013TRLO0.1.1
21/12/2023 10:58:19 240 149 BATE 00383371014TRLO0.1.1
21/12/2023 10:58:19 189 149.2 TRQX 00383371015TRLO0.1.1
21/12/2023 10:58:19 1734 148.6 XLON 00383371016TRLO0.1.1
21/12/2023 12:16:48 472 148.8 CHIX 00383378822TRLO0.1.1
21/12/2023 12:16:48 578 148.8 XLON 00383378823TRLO0.1.1
21/12/2023 12:16:48 590 148.8 XLON 00383378825TRLO0.1.1
21/12/2023 12:16:48 1156 148.8 XLON 00383378824TRLO0.1.1
21/12/2023 12:16:49 1493 148.8 XLON 00383378826TRLO0.1.1
21/12/2023 12:16:49 267 148.8 XLON 00383378827TRLO0.1.1
21/12/2023 12:18:16 712 148.8 XLON 00383378977TRLO0.1.1
21/12/2023 12:18:16 267 148.8 XLON 00383378978TRLO0.1.1
21/12/2023 12:25:17 4 148.8 XLON 00383379636TRLO0.1.1
21/12/2023 12:50:13 358 148 AQXE 00383382990TRLO0.1.1
21/12/2023 12:50:13 189 148 TRQX 00383382992TRLO0.1.1
21/12/2023 12:50:13 474 148 BATE 00383382991TRLO0.1.1
21/12/2023 12:50:13 2447 148 XLON 00383382993TRLO0.1.1
21/12/2023 12:57:42 1734 147 XLON 00383383913TRLO0.1.1
21/12/2023 12:58:28 578 147.4 CHIX 00383383980TRLO0.1.1
21/12/2023 12:58:28 408 147.4 XLON 00383383981TRLO0.1.1
21/12/2023 12:58:28 170 147.4 XLON 00383383982TRLO0.1.1
21/12/2023 13:58:28 152 149.2 XLON 00383393821TRLO0.1.1
21/12/2023 14:13:52 213 149.8 CHIX 00383397373TRLO0.1.1
21/12/2023 14:13:52 671 149.8 CHIX 00383397374TRLO0.1.1
21/12/2023 14:49:09 90 152.2 XLON 00383407261TRLO0.1.1
21/12/2023 14:53:06 578 151.6 CHIX 00383408592TRLO0.1.1
21/12/2023 14:53:06 1242 151.6 XLON 00383408593TRLO0.1.1
21/12/2023 14:53:06 508 151.4 BATE 00383408594TRLO0.1.1
21/12/2023 14:53:06 578 151.4 BATE 00383408595TRLO0.1.1
21/12/2023 14:53:10 189 151.2 TRQX 00383408628TRLO0.1.1
21/12/2023 14:53:10 213 151.4 AQXE 00383408631TRLO0.1.1
21/12/2023 14:53:10 503 151.6 AQXE 00383408632TRLO0.1.1
21/12/2023 14:53:20 35 151.2 XLON 00383408681TRLO0.1.1
21/12/2023 14:53:26 9 151.2 XLON 00383408710TRLO0.1.1
21/12/2023 14:53:26 36 151.2 XLON 00383408711TRLO0.1.1
21/12/2023 14:56:03 559 151.2 XLON 00383409806TRLO0.1.1
21/12/2023 14:56:09 4 151 AQXE 00383409842TRLO0.1.1
21/12/2023 15:16:43 1356 151.4 CHIX 00383417663TRLO0.1.1
21/12/2023 15:32:30 1696 151.4 CHIX 00383423441TRLO0.1.1
21/12/2023 15:33:12 1026 151.6 CHIX 00383423731TRLO0.1.1
21/12/2023 15:33:22 31 151.6 CHIX 00383423789TRLO0.1.1
21/12/2023 15:33:39 213 151.6 CHIX 00383423963TRLO0.1.1
21/12/2023 15:33:55 213 151.6 CHIX 00383424105TRLO0.1.1
21/12/2023 15:37:30 213 151.6 CHIX 00383426131TRLO0.1.1
21/12/2023 15:37:30 350 151.6 CHIX 00383426132TRLO0.1.1
21/12/2023 15:47:17 578 151 BATE 00383430747TRLO0.1.1
21/12/2023 15:47:17 578 151.2 CHIX 00383430746TRLO0.1.1
21/12/2023 15:47:17 395 151 BATE 00383430748TRLO0.1.1
21/12/2023 15:47:17 354 151 AQXE 00383430750TRLO0.1.1
21/12/2023 15:47:17 477 151.2 XLON 00383430749TRLO0.1.1
21/12/2023 15:47:17 358 151 AQXE 00383430751TRLO0.1.1
21/12/2023 15:47:17 1728 151.2 XLON 00383430753TRLO0.1.1
21/12/2023 15:47:17 107 151.2 XLON 00383430752TRLO0.1.1
21/12/2023 15:47:17 189 151 TRQX 00383430754TRLO0.1.1
21/12/2023 15:47:17 189 151 TRQX 00383430755TRLO0.1.1
21/12/2023 15:51:29 1110 150.4 CHIX 00383432741TRLO0.1.1
21/12/2023 15:51:29 2312 150.4 XLON 00383432742TRLO0.1.1
21/12/2023 15:51:41 189 150.6 TRQX 00383432837TRLO0.1.1
21/12/2023 15:53:34 21 150.6 BATE 00383433681TRLO0.1.1
21/12/2023 15:53:34 189 150.8 BATE 00383433682TRLO0.1.1
21/12/2023 16:03:22 8 151 AQXE 00383438358TRLO0.1.1
21/12/2023 16:03:52 8 150.8 AQXE 00383438538TRLO0.1.1
21/12/2023 16:19:47 213 151 AQXE 00383446136TRLO0.1.1
21/12/2023 16:29:24 137 151 AQXE 00383451700TRLO0.1.1
21/12/2023 16:29:45 350 151 AQXE 00383452193TRLO0.1.1
21/12/2023 16:29:49 754 150.8 BATE 00383452365TRLO0.1.1
21/12/2023 16:29:49 309 150.8 BATE 00383452366TRLO0.1.1
21/12/2023 16:29:49 470 150.8 CHIX 00383452367TRLO0.1.1
21/12/2023 16:29:49 557 150.8 CHIX 00383452368TRLO0.1.1
21/12/2023 16:29:49 547 150.8 CHIX 00383452370TRLO0.1.1
21/12/2023 16:29:49 4 150.8 CHIX 00383452369TRLO0.1.1
21/12/2023 16:29:51 1953 150.6 XLON 00383452412TRLO0.1.1
21/12/2023 16:29:51 192 150.6 TRQX 00383452413TRLO0.1.1
21/12/2023 16:29:51 33 150.6 TRQX 00383452414TRLO0.1.1
21/12/2023 16:29:51 269 150.6 XLON 00383452415TRLO0.1.1
21/12/2023 16:29:51 64 150.6 XLON 00383452416TRLO0.1.1
21/12/2023 16:29:55 153 150.6 TRQX 00383452507TRLO0.1.1
21/12/2023 16:29:55 329 150.6 XLON 00383452508TRLO0.1.1
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSFLFEDFRLLFIVRecent news on Puretech Health
See all newsRCS - PureTech Health PLC - PRTC's Vedanta Begins Phase 3 of VE303 in C. diff
AnnouncementREG - PureTech Health PLC - Tender Offer
AnnouncementRCS - PureTech Health PLC - PRTC's Seaport Presents Ph1 and Ph2a SPT-300 Data
AnnouncementRCS - PureTech Health PLC - PRTC's Seaport Announces Board/Team Appointments
AnnouncementREG - PureTech Health PLC - Total Voting Rights
Announcement